Drug intelligence / Profile preview

enterovirus 71 vaccine (vero cell), inactivated

Development stage
Phase 4
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Enterovirus 71 vaccine (vero cell), inactivated is an inactivated, whole-virus vaccine produced using vero cells and inactivated with formalin. It is designed to induce protective immunity against enterovirus 71 (EV-A71), which is a major causative agent of hand, foot, and mouth disease (HFMD). The vaccine works primarily by stimulating production of neutralizing antibodies against the VP1 capsid protein of EV-A71, conferring immunity and preventing severe outcomes, especially in children under five. The product was developed and licensed mainly in China, with three primary manufacturers (Sinovac Biotech, Beijing Vigoo, and Chinese Academy of Medical Science) having received approval from the Chinese NMPA following large-scale phase III trials. Its efficacy in preventing EV-A71-associated HFMD and severe neurologic complications is very high (90–100%) among young children[1][3][5].

Brand names
Sinovac EV71 vaccineVigoo EV71 vaccine
Other names
inactivated enterovirus 71 vaccineinactivated EV71 vaccineenterovirus 71 inactivated vaccineenterovirus71 inactivated vaccineenterovirus-71 inactivated vaccineformalin-inactivated EV71 vaccine

Beyond the preview

Go deeper on enterovirus 71 vaccine (vero cell), inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enterovirus 71 vaccine (vero cell), inactivated.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call